Humacyte’s (HUMA) “Buy” Rating Reiterated at TD Cowen

TD Cowen restated their buy rating on shares of Humacyte (NASDAQ:HUMA) in a report published on Friday, Benzinga reports. The firm currently has a $10.00 price target on the stock.

Other equities research analysts have also recently issued reports about the stock. Benchmark restated a “buy” rating and set a $15.00 price target on shares of Humacyte in a report on Thursday, October 10th. Cantor Fitzgerald reissued an “overweight” rating and set a $13.00 price objective on shares of Humacyte in a research report on Friday, September 20th. BTIG Research reaffirmed a “buy” rating and issued a $10.00 target price on shares of Humacyte in a report on Friday. Finally, EF Hutton Acquisition Co. I upgraded Humacyte to a “strong-buy” rating in a report on Monday, September 9th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $10.00.

Humacyte Stock Up 3.5 %

Shares of HUMA stock opened at $5.03 on Friday. The stock’s 50 day simple moving average is $5.78 and its 200 day simple moving average is $5.93. Humacyte has a twelve month low of $1.96 and a twelve month high of $9.97. The company has a debt-to-equity ratio of 0.61, a quick ratio of 5.41 and a current ratio of 5.41. The company has a market capitalization of $598.99 million, a price-to-earnings ratio of -5.03 and a beta of 1.45.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). As a group, research analysts predict that Humacyte will post -1.09 EPS for the current year.

Insider Activity at Humacyte

In other Humacyte news, Director Brady W. Dougan sold 252,676 shares of the company’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $6.71, for a total value of $1,695,455.96. Following the completion of the transaction, the director now owns 4,306,464 shares of the company’s stock, valued at $28,896,373.44. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other Humacyte news, Director Brady W. Dougan sold 252,676 shares of the business’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $6.71, for a total value of $1,695,455.96. Following the sale, the director now owns 4,306,464 shares of the company’s stock, valued at $28,896,373.44. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Dale A. Sander sold 39,389 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $6.68, for a total transaction of $263,118.52. Following the transaction, the chief financial officer now directly owns 2,000 shares of the company’s stock, valued at $13,360. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,084,153 shares of company stock worth $6,869,996 over the last three months. Company insiders own 23.10% of the company’s stock.

Institutional Investors Weigh In On Humacyte

Institutional investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC lifted its position in shares of Humacyte by 693.0% during the 2nd quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock worth $2,881,000 after buying an additional 524,600 shares during the period. Virtu Financial LLC bought a new position in shares of Humacyte during the first quarter valued at $197,000. Private Advisor Group LLC boosted its stake in shares of Humacyte by 232.7% in the 1st quarter. Private Advisor Group LLC now owns 317,624 shares of the company’s stock valued at $988,000 after purchasing an additional 222,144 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Humacyte by 28.7% in the 1st quarter. Vanguard Group Inc. now owns 4,019,681 shares of the company’s stock worth $12,501,000 after purchasing an additional 896,415 shares during the last quarter. Finally, Millennium Management LLC increased its position in shares of Humacyte by 504.3% during the 2nd quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock worth $7,677,000 after purchasing an additional 1,334,641 shares in the last quarter. 44.71% of the stock is owned by institutional investors and hedge funds.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.